SGLT2 inhibitors vs placebo
Kidney composite outcome median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower kidney composite outcome median compared with placebo (high certainty).
1 finding from 1 review
- Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes onlyRR 0.68 [0.59, 0.78]7 studies · 36380 participantsHigh